Targeted binding agents against B7-H1

Patent metadata

Field	Value
Publication number	US-11518809-B2
Application number	US-201916519614-A
Country	US
Kind code	B2
Filing date	Jul 23, 2019
Priority date	Nov 24, 2009
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

First claim

The invention claimed is:

1. An isolated antibody or fragment thereof that specifically binds to B7-H1, wherein the antibody or fragment thereof comprises:
a VH CDR1 consisting of the amino acid sequence of SEQ ID NO: 3,
a VH CDR2 consisting of the amino acid sequence of SEQ ID NO: 4,
a VH CDR3 consisting of the amino acid sequence of SEQ ID NO: 5,
a VL CDR1 consisting of the amino acid sequence of SEQ ID NO: 8,
a VL CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and
a VL CDR3 consisting of the amino acid sequence of SEQ ID NO: 10; or
a VH CDR1 consisting of the amino acid sequence of SEQ ID NO: 63,
a VH CDR2 consisting of the amino acid sequence of SEQ ID NO: 64,
a VH CDR3 consisting of the amino acid sequence of SEQ ID NO: 65,
a VL CDR1 consisting of the amino acid sequence of SEQ ID NO: 68,
a VL CDR2 consisting of the amino acid sequence of SEQ ID NO: 69, and
a VL CDR3 consisting of the amino acid sequence of SEQ ID NO: 70.

2. The antibody or fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody or fragment thereof of claim 2 , wherein the antibody is a fully human monoclonal antibody.

4. The antibody or fragment thereof according to any one of the preceding claims, wherein the antibody or fragment thereof comprises a heavy chain variable domain consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain variable domain consisting of the amino acid sequence of SEQ ID NO: 7; or a heavy chain variable domain consisting of the amino acid sequence of SEQ ID NO: 62 and a light chain variable domain consisting of the amino acid sequence of SEQ ID NO: 67.

5. The antibody or fragment thereof of claim 4 , wherein the fragment is a binding fragment selected from the group consisting of a Fab, Fab′, F(ab′)2, Fv and dAb fragment.

6. The antibody or fragment thereof of claim 4 , wherein the Fc region of the antibody is characterized by the residues of 234F, 235E, and 331S, as numbered by the EU index as set forth in Kabat.

7. A nucleic acid molecule encoding the antibody of claim 1 .

8. An isolated host cell transfected with a vector comprising the nucleic acid molecule of claim 7 .

9. An antibody produced by a method comprising, culturing the host cell of claim 8 , expressing an antibody encoded by the nucleic acid molecule of claim 7 , and isolating the antibody from the culture.

10. A composition comprising the antibody of claim 1 .

11. A pharmaceutical composition comprising the antibody of claim 1 and pharmaceutically acceptable carrier.

Assignees

• Medimmune Ltd

Inventors

• Queva Christophe
• Morrow Michelle
• Hammond Scott
• Alimzhanov Marat
• Babcock John
• Foltz Ian
• Kang Jaspal Singh
• Sekirov Laura
• Boyle Melanie
• Chodorge Matthieu
• Stewart Ross A
• Mulgrew Kathleen Ann

Classifications

• A61P31/18

  for HIV · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2827 Primary

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/70

  characterized by effect upon binding to a cell or to an antigen · CPC title